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Abstract: The recent evidence-based shift towards an algorithm of early initiation and 
aggressive titration of insulin therapy in the management of type 2 diabetes requires the use 
of an effective insulin formulation that is both safe and acceptable to patients and physicians 
alike. The advent of the long-acting insulin analogues, insulin detemir and glargine, in the last 
decade has revolutionized insulin therapy in type 2 diabetes. Their unique pharmacokinetic and 
pharmacodynamic properties have offered tangible advantage over the conventional intermediate 
and long-acting insulin preparations in terms of improving glucose control as well as reducing 
risk of hypoglycemia and weight gain. This review focuses on the pharmacodynamic properties 
of the long-acting insulin analogue detemir, the outcome of studies on its relative efficacy and 
safety as well as its proposed place in the management of type 2 diabetes.
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Introduction to management of type 2 diabetes
The benefits of intensive glucose lowering treatment in reducing the risk of microvascular 
complications in both type 1 and type 2 diabetes has already been confirmed from the 
outcome of the landmark Diabetes Control and Complications Trial (DCCT) and United 
Kingdom Prospective Diabetes Study (UKPDS) trials.1,2 A recent 10-year follow-up 
study of the UKPDS cohort also showed long-term beneficial effects of intensive glucose 
control in reducing cardiovascular and all cause mortality.3  In recognition of these facts, 
a tighter glycemic target has been recommended by the American Diabetes Associa-
tion (ADA) and International Diabetes Federation (IDF) aiming for HbA1c of 7% and 
6.5% respectively.4,5 However, studies have shown that more than two thirds of patients 
with type 2 diabetes fail to meet the recommended HbA1c target of 7% despite half of 
this population being on at least two oral antidiabetes agents (OADs).6
Although a dietary and exercise program with or without metformin constitutes to 
be the first line treatment for the majority of newly diagnosed type 2 diabetes patients, 
most of these patients will eventually require the addition of insulin therapy due to 
progressive decline in beta cell function.7 The joint ADA/ European Association for 
the Study of Diabetes (EASD) consensus statement on treatment for type 2 diabetes 
therefore recommends the early initiation of insulin therapy in the form of basal insulin 
combined with OADs to achieve optimal glucose control.8
Limitations of insulin therapy
In addition to the fear of needles, the risk of hypoglycemia and weight gain remains 
a major obstacle towards initiation and titration of insulin treatment. Hypoglycemia Vascular Health and Risk Management 2009:5 554
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is widely considered as a main factor that limits the scope 
for aggressive insulin therapy. In the DCCT, the relative 
risk of severe hypoglycemia for type 1 diabetes patients 
who received intensive insulin therapy was 3.28 greater 
compared to those who were on conventional therapy.1 
Similarly, in the UKPDS trial, patients assigned to intensive 
insulin treatment had a higher annual incidence of major 
hypoglycemia (1.8%).2
Insulin associated weight gain is also of particular 
concern in type 2 diabetes, a condition in which 80% to 
90% of the population is already overweight.9 In UKPDS, 
patients who received intensive insulin therapy gained more 
weight (4 kg) compared to those in the conventional treat-
ment group. Moreover, the rate of weight gain was noted to 
be at its fastest during the initial phase of insulin treatment, 
which is a crucial time of adjustment for the insulin-naive 
patient thereby potentially influencing long-term compliance. 
The predominantly central or visceral distribution of insulin 
associated weight gain is correlated with increased insulin 
resistance and cardiovascular risk, further undermining the 
benefits of improved glucose control.10,11 Weight gain is also 
adversely affects blood pressure and lipid profile.12–15
The proposed mechanisms for insulin associated weight 
gain are multiple including defensive snacking to avert hypo-
glycemia, calorie retention from decreased glycosuria and the 
abnormal peripheral to hepatic insulin balance that exists with 
exogenous insulin use leading to increased hepatic glucose 
output and peripheral lipogenesis.16–18 The main predictors 
of insulin related weight gain are high initial glycemic level, 
degree of improvement in glucose control, number of insulin 
injections and mean daily insulin dose.13,19 Thus, the patients 
who are at risk for insulin associated weight gain are the very 
ones who need insulin the most (those with poor control) and 
those who have responded well to treatment.
Basal insulin therapy in type 2 
diabetes
An ideal insulin therapy regime would mimic the normal 
physiology of endogenous insulin production characterized 
by a smooth peak-less basal delivery of insulin in the fasting 
and interprandial state to suppress hepatic gluconeogenesis 
along with prandial boosts of insulin to prevent meal related 
glucose excursions. The so-called basal-bolus regimen of 
insulin therapy, which is widely used in both type 1 and 
type 2 diabetes, employs this physiologic concept by com-
bining a long-acting basal insulin with short acting prandial 
insulin formulations. Basal insulin can also be used in 
conjunction with insulin sensitizing OADs in type 2 diabetes. 
This latter approach has been shown to be effective in limiting 
insulin requirements, minimizing weight gain and offer some 
cardiovascular protective effect.20,21
Until the recent advent of long-acting insulin analogues, 
basal insulin therapy was only available in the form of zinc or 
protamine retarded preparations of porcine or human insulin. 
Upon subcutaneous injection, the suspended precipitates 
of these insulin formulations slowly dissolve to prolong 
absorption into the peripheral circulation and provide a low 
but continuous supply of basal insulin in the fasting state. 
However, conventional intermediate and long-acting human 
basal insulin preparations such as neutral protamine hagedorn 
(NPH) fall short of the ideal physiologic smooth delivery 
of basal insulin because of their poor pharmacokinetics 
profile characterized by pronounced peaks (4 to 20 hours 
after injection) and marked intrasubject variability which 
predisposes patients to hypoglycemia (Table 1).
Hypoglycemia is therefore not a direct consequence of 
intensive glucose control strategy but a reflection of the inherent 
pharmacodynamic shortcomings of conventional insulin 
preparations to closely match insulin levels to physiological 
needs. To this end, the introduction of the basal insulin analogues 
detemir and glargine with no significant peak activity, longer 
duration of action, less variability and hence lower risk of 
hypoglycemia has been a welcome development.
Insulin detemir, pharmacokinetics 
and pharmacodynamics
Insulin detemir [B29Lys(myristoyl), des (B30)] is a 
long-acting insulin analogue produced by recombinant DNA 
technology that involves the deletion of the amino acid 
threonine at the B-30 locus and the acylation of a 14-carbon 
fatty acid called myristic acid to lysine at B-29 locus of the 
insulin molecule (Figure 1). This structural modification of 
the human insulin molecule allows self association of hexam-
ers within the injection depot as well as promoting reversible 
binding to albumin in the plasma and interstitial fluid which 
mediates its slow absorption from the subcutaneous site 
leading to protracted duration of action.22,23
Its soluble nature removes the need for resuspension and 
the potential for precipitation upon injection which accounts 
for its reproducible and predictable action. Detemir’s revers-
ible binding to albumin also buffers short-term changes in 
absorption rates from the subcutaneous tissue, additional 
mechanism that explains its tendency for reduced intrapatient 
variability compared to NPH and insulin glargine.24,25 Insulin 
glargine is another long-acting insulin analogue produced by 
adding two arginine residues to the C-terminus of the B-chain Vascular Health and Risk Management 2009:5 555
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and replacing the asparagine residue at A-21 with a neutral 
glycine residue, rendering it less soluble at the physiological 
pH of subcutaneous tissue and delaying absorption with 
duration of action of up to 24 hours.26
An additional proposed benefit of detemir’s binding to 
albumin is restoration of the normal hepatic to peripheral 
insulin gradient. Unlike endogenous insulin, conventional 
insulin preparations such as NPH partly bypass first pass 
hepatic clearance which explains their pronounced effect on 
peripheral targets such as adipose tissue and muscle. Insulin 
detemir however displays delayed transfer to peripheral tissues 
by virtue of its albumin binding property that exposes the liver 
to relatively higher levels of insulin.27 This mechanism not only 
limits hyperglycemia by decreasing hepatic glucose output, but 
also potentially reduces insulin-related weight gain.28
Its onset of action of 2 hours is comparable to both NPH 
and insulin glargine but in common with the latter, it lacks 
pronounced peak due to its favorable pharmacokinetic and 
pharmacodynamic properties. Isoglycemic studies have 
confirmed that duration of action is dose dependent, lasting 
up to 20 hours for doses of more than 0.4 units/kg making 
a once daily dosing feasible. However for doses less than 
0.4 units/kg, the duration of action is shorter hence twice 
daily dosing is recommended.25
Efficacy and safety of insulin 
detemir
Several studies conducted to assess the efficacy and safety 
of insulin detemir in type 1 diabetes have demonstrated 
that detemir offers comparable levels of HbA1c reduction to 
both NPH and glargine as well as achieving better fasting 
plasma glucose (FPG) levels and less intrapatient variability 
compared to NPH.29–34 Moreover, these favorable outcomes of 
detemir were accompanied by a lower risk of hypoglycemia 
in overall and nocturnal hypoglycemia.29–34
The relative efficacy and safety of insulin detemir in type 2 
diabetes has also been investigated in multinational, open-label, 
randomized trials. These studies compared insulin detemir 
to NPH and insulin glargine either as part of basal-bolus 
regimen or as an add-on to OADs. The major outcomes of 
these studies are summarized in Table 2.
Glycemic control
Raslova et al conducted a randomized study comparing once 
or twice daily insulin detemir added to prandial insulin aspart 
with once or twice daily NPH and prandial regular human 
insulin (RHI) in 395 type 2 diabetic patients.35 At the end of 
the study duration of 22 weeks, reductions in HbA1c levels 
achieved with the detemir based regimen were comparable 
to that of NPH based regimen (8.2% to 7.5% vs 8.1% 
to 7.5% respectively). Similarly, comparable FPG levels were 
achieved with the two insulin treatment regimes.
Table 1 Pharmacokinetics of intermediate and long-acting insulin 
preparations
Type of insulin Onset Peak effect Duration (hours)
intermediate-acting
  Semilente 0.5–1 4–6 8–12
  Lente 2–4 6–10 12–24
  isophane/NPH 2–4 6–10 12–24
Long-acting
  Ultralente 3–4 8–20 20–36
  Protamine zinc 3–4 14–20 24–36
Long-acting analogues
  Glargine 2 no pronounced 
peak
22
  Detemir 2 no pronounced 
peak
20 for doses  
0.4 units/kg
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
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Figure 1 insulin detemir.Vascular Health and Risk Management 2009:5 556
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Table 2 Randomized trials comparing insulin detemir to NPH and glargine in basal-bolus regimen and as add-on to OADS
Study Study duration 
(weeks)
Number 
of patients
Insulin therapy Change in 
HbA1c  (%)
Incidence (%)  
of hypoglycemia
Change in weight  
(kg)
Majora Nocturnal
Philis-Tsimikas et al38 20 165
169
164
detemird 
detemire
NPH
−1.6
−1.5 
−1.7
0 
1.2 
0
2.4 
4.7 
13.4
+1.2 
+1.5 
+1.6
Hermansen et al37 26 227 
225
detemir + OADs 
NPH + OADs
−1.8 
−1.9
NA 
NA
55% less 
NA
+1.2 
+2.8
Rosenstock et al39  52 291 
291
detemir + OAD 
Glargine
−1.4 
−1.5
0/pt-yr 
NA
1.3/pt-yr 
1.3/pt-yr
+3.0 
+3.9
Haak et al36 26 341
164
detemir + aspart 
NPH + aspart
−0.2
−0.4
2
2
15.8
23.6
+1.0
+1.8
Raslova et al35 22 195 detemir and aspart −0.7 1.1 14.9 +0.51
199 NPH and RHi −0.6 0.5 17.5 +1.13
Rosenstock et al39 52 582 detemir and OAD 
glargine and OAD 
−1.4 
−1.5
no significant 
difference
+3.0
+3.9
aMajor hypoglycemia is where patients are not able to treat themselves.
dinsulin detemir administered in the morning.
einsulin detemir administered in the evening.
In a study of similar design undertaken by Haak et al 505 
type 2 diabetic patients taking insulin aspart with once or 
twice daily detemir or NPH were followed up for 26 weeks 
duration.36 There was no significant difference in HbA1c and 
fasting blood glucose (FBG) level reduction from baseline 
achieved with the detemir and NPH based regimes (7.9 to 
7.6% vs 7.8% to 7.5% and –0.5 vs –0.6 mmol/L respectively).
Two other randomized studies compared the efficacy of 
insulin detemir to that of NPH when used as basal therapy 
added to OADs. The first of these by Hermansen et al 
assessed the efficacy of twice daily insulin detemir added to 
OADs in comparison with twice daily NPH plus OADs in 
475 type 2 diabetes patients inadequately controlled on OAD 
therapy alone.37 Comparable reductions from baseline in both 
HbAlc and FBG were achieved with the two regimes (detemir: 
from 8.6% to 6.8% and 11.1 to 6.9 mmol/L; NPH 8.5% 
to 6.6% and 10.8 to 6.6 mmol/L). Philis-Tsimikas et al 
conducted a 20 weeks multicenter 3-arm study enrolling a 
total of 504 insulin naive poorly controlled type 2 diabetes 
patients randomized to receive evening detemir, prebreakfast 
detemir or evening NPH added to OADs.38 There was no 
significant difference in HbA1c reduction from baseline in 
the 3 arms of the study (–1.58%, –1.48% and –1.78% for the 
morning detemir, evening detemir and NPH respectively).
A 52-week randomized open-label noninferiority study 
by Rosenstock et al comparing a once daily regimen of 
insulin detemir and glargine added to OADs in 582 insulin 
naive type 2 diabetic patients.39 Patients were randomized 
to receive either of the two basal insulin on a 1:1 ratio 
and insulin dose was titrated aiming for a fasting glucose 
of 6 mmol/L. Those patients randomized to receive detemir 
were allowed a second dose if premeal evening glucose 
levels were 7 mmol/L, 55% of detemir patients completed 
the study on twice daily. Mean daily detemir dose was higher 
glargine.39 At the end of the study period, there was no 
significant difference in HbA1c level and FPG achieved in the 
two arms (8.6% to 7.2% and 7.1%; 10.8 mmol/L to 7.1 and 
7.2 mmol/L). Another more recent trial once-daily dosing of 
insulin detemir provided 24-hour glycemic control, assessed 
by continuous glucose monitoring, similar to that of insulin 
glargine in patients with type 2 diabetes.40
Risk of hypoglycemia
The risk of hypoglycemia is one of the unwanted consequences 
of the treatment algorithm for early initiation and aggressive 
titration of insulin therapy in type 2 diabetes. This risk is 
particularly pronounced with conventional intermediate and 
long-acting insulin preparations such as NPH and ultralente 
due to peak activity and unpredictable profile. The smooth 
pharmacokinetic profile of the long-acting insulin analogues 
detemir and glargine delivers a relatively predictable and 
peak-less insulin level which is less prone to inflicting 
hypoglycemia.
In the two studies by Raslova et al and Haak et al 
which compared once or twice daily detemir with once or 
twice daily NPH in a basal-bolus regimen, there was no 
significant difference in the risk of   both overall and nocturnal 
hypoglycemia between the two groups.35,36  However, the trial Vascular Health and Risk Management 2009:5 557
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conducted by Hermansen et al comparing insulin detemir 
with NPH as add-on to OADs showed a 55% less risk of 
nocturnal hypoglycemia in favor of detemir for comparable 
levels of improvements in glucose control.37 Similarly, 
in the study by Philis-Tsimikas et al evening detemir 
produced a 53% and 65% reduction in overall and nocturnal 
hypoglycemia respectively compared to evening NPH.38 The 
risk of nocturnal hypoglycemia was even much lower when 
detemir was administered in the morning (87%). There was 
however no significant difference in risk of hypoglycemia 
between morning and evening detemir. The risk of hypo-
glycemia was also not significantly different when insulin 
detemir is compared with glargine as add-on to OADS.39
Within-subject variability
Variability in glucose profile is a measure of the degree of 
difference in the glucose-lowering effect of a given dose 
of insulin from one injection to another in the same patient 
at a specific point in time.41 It is often expressed in terms 
of the number of standard deviations from the median or 
mean glucose level obtained at a given time. A variable 
or unpredictable glucose level profile increases the risk of 
hypoglycemia and hence makes it difficult to safely titrate 
insulin dose to achieve optimal glucose control targets.42,43
Euglycemic clamp studies have shown that detemir is 
associated with less within-subject variability compared to 
NPH in both type 1 and type 2 diabetes.44,45 Clinical studies in 
patients with type 2 diabetes have also supported this obser-
vation. In the study by Raslova et al for instance, within-
subject variability in FBG with the use of insulin detemir 
with aspart was significantly less compared to NPH plus RHI 
(SD: 1.2 vs 1.5 mmol/L respectively, p  0.001).35 Similarly, 
the study by Haak et al also demonstrated less within-subject 
variability in FBG with the use of insulin detemir plus aspart 
than NPH plus aspart (SD: 1.3 vs 1.4 mmol/L, p = 0.021).36 
However, in the study by Hermansen et al comparing 
insulin detemir to NPH as add-on to OADs, there was no 
significant difference in within-subject variability between 
the two groups.37 Within-subject variability was also not 
significantly different between insulin detemir and glargine 
added to OADs in the study by Rosenstock et al.39
Reduced insulin-related weight gain
Insulin therapy in type 2 diabetes is commonly associated 
with weight gain, the magnitude of which depends on the 
total dose and type of insulin formulation used. As already 
discussed in previous sections, insulin detemir has favorable 
pharmacodynamic properties that are thought to provide a 
theoretical weight neutral advantage over the conventional 
basal insulin preparations.
The randomized trials comparing insulin detemir to NPH 
in type 2 diabetes both as basal-bolus regimen and as add-on 
to OADs revealed less weight gain for equivalent level of 
glucose control in favor of detemir (p  0.001 to 0.05).35–38 
Insulin detemir has likewise caused less weight gain com-
pared to glargine when added to oral agents at comparable 
level of glucose control (p  =  0.012). However, this difference 
was primarily related to completers on once daily detemir 
dose (45% of insulin detemir group completed the study on 
once daily dose who received less total daily insulin dose 
compared with the other 55% completed the study on twice 
daily detemir dose).39
In a more recent multinational, 52-week, open-label, 
parallel-group, noninferiority, treat-to-target trial Hollander 
et al compared insulin detemir to glargine in patients with a 
diagnosis of type 2 diabetes for 12 months or more who had 
been receiving an OADs or insulin, with or without OADs, 
for more than 4 months were randomized in a 2:1 ratio to 
receive detemir or glargine.46 At 52 weeks, Mean weight 
gain was significantly lower with detemir than with glargine 
(2.8 vs 3.8 kg; mean difference, –1.04; 95% CI –2.08 to 
–0.01; P  0.05). There was no significant difference 
between detemir and glargine in terms of change in fasting 
sugar (7.19% and 7.03%, respectively) or risk of hypogly-
cemia. The reduction in HbA1c was not significantly affected 
by whether detemir was administered once or twice daily. 
At 52 weeks mean HbA1c and mean decrease in HbAlc from 
baseline were more in insulin glargine group but non of 
these differences reached statistical significance.46 Although 
the magnitude of differences in weight gain between insulin 
detemir and the other basal insulins in the five studies outlined 
above appears too modest to be clinically relevant, the results 
have to be interpreted in the context of the short duration 
of follow-up of the studies (mean duration ≃ 33 wks).
The PREDICTIVE (Predictable 
Results and Experience in  
Diabetes through Intensification 
and Control to Target: an 
International Variability Evaluation)
This is an ongoing large scale, multi-national, open label, 
prospective, observational study designed to assess the 
safety and efficacy of insulin detemir in day to day clinical 
practice.47 This study takes place in 20 countries and it is 
expected to enlist a population of over 30,000 patients. Vascular Health and Risk Management 2009:5 558
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The subjects of this study include both type 1 and type 2 
diabetes patients who are prescribed insulin detemir as 
part of routine clinical care. The primary endpoints for this 
study are serious adverse drug reactions, including major 
hypoglycemic episodes whereas the secondary endpoints 
include overall and nocturnal hypoglycemia, HbA1c, mean 
self-monitored fasting glucose, fasting glucose variability 
(calculated as the standard deviation of the last two to six 
fasting glucose measurements) and weight change.
So far, the outcomes of only a few subgroup analysis 
of the European PREDICTIVE cohorts have been released. 
The first of these is a 12-week subgroup analysis of the 
German cohort of 1832 type 2 diabetic patients who were 
transferred to insulin detemir with or without OADs from 
either an OAD only regimen (n = 1321), NPH insulin 
with or without OADs (n = 251) or insulin glargine with 
or without OADs (n = 260) by their physicians as part of 
routine clinical care.48 Three months after starting insulin 
detemir, no major hypoglycemic events occurred in any of 
the three groups. Overall nocturnal hypoglycemic events 
per patient were reduced by 84%, 80% and 90% for OADs 
only, NPH ± OADs and glargine ± OADs groups respec-
tively compared to baseline. In addition, both HbA1c and 
fasting blood glucose levels were significantly reduced for 
all the subgroups (P  0.0001). Fasting blood glucose vari-
ability was likewise significantly less marked with the use 
of insulin detemir compared to baseline for all the subgroups 
(P  =  0.0008). The improvement in glycemic control 
observed with the use of insulin detemir in this analysis 
was also accompanied by a combined weight reduction of 
0.9 kgs across the subgroups (P  0.0001).
In a preliminary report of a 3 month follow-up data 
from the Danish PREDICTIVE cohort of 312 type 1 
and 77 type 2 diabetes patients, the incidence of major 
hypoglycemic episodes was reduced from 3.9/patient-
years at baseline to 0.4/patient-years at follow-up in type 1 
patients (P  0.0001), and from 1.0 to 0.0/patient-years in 
type 2 patients (P = 0.125).49 The mean incidence of overall 
and nocturnal hypoglycemic episodes was also reduced in 
both type 1 (−37.4 and −17.7/patient-years, P  0.0001 for 
both) and type 2 patients (−17.7 and −7.8/patient-years, 
P = 0.0012 and P = 0.0020, respectively).
In a 12-week follow-up report on a Turkish PREDICTIVE 
cohort of 1285 type 1 and 777 type 2 diabetes patients 
switched from once or twice daily glargine (±OADs) to once 
daily detemir in a basal-bolus regimen, significant reductions 
in both HbA1c and FPG was obtained across the groups 
without any significant change in body weight. There was also 
significant reduction in overall and nocturnal hypoglycemic 
episode rates in favor of detemir (P  0.0001).50
Another subgroup analysis of 2377 OAD treated 
type 2 diabetes patients of the European cohort of the 
PREDICTIVE study was reported after a mean follow-up of 
14 weeks duration.51 These patients were prescribed insulin 
detemir as basal therapy with or without OADs. Compared to 
baseline, treatment with insulin detemir significantly reduced 
HbA1c, fasting glucose and within-patient fasting glucose 
variability (–1.3%, –3.7 mmol/L, –0.5 mmol/L respectively; 
P  0.0001).There was also a small reduction in mean body 
weight (–0.7 kg; P  0.001).There was only one serious 
adverse drug reaction in the form of a major hypoglycemic 
episode in the detemir-treated group.
This ongoing observational study is widely anticipated 
to provide us ample evidence regarding the safety and 
efficacy of insulin detemir in routine clinical use and the 
relative benefits it offers in comparison with the other 
basal insulin preparations so as to guide clinicians to make 
rational choices. However, the study is open label and not 
randomized. Furthermore, lack of a control group is not 
ideal and improvement in diabetes care after enrolment in a 
clinical trial can be significant confounding factor and should 
be considered before making final conclusions from this 
project.
Conclusion
Insulin detemir is a novel soluble long-acting insulin ana-
logue which is proven to be both safe and effective for 
use in type 2 diabetes. Its unique pharmacokinetic and 
pharmacodynamic properties provide a more predictable 
glucose profile and less risk of hypoglycemia compared to 
NPH when it is used in a basal-bolus regimen or as add-
on to OADs. It has also been proven to have a modest yet 
significant advantage over both NPH and glargine in terms 
of treatment related weight gain. Although the magnitude 
of the differences in weight gain between insulin detemir 
and the other basal insulins appears too modest to be clini-
cally relevant, this has to be interpreted in the context of the 
relatively short duration of follow-up of the studies. More 
data needed on the long-term effect of insulin detemir on 
treatment related weight gain compared with other basal 
insulins and if this weight advantage achieved will become 
more significant clinically or be maintained long term at all. 
The long-term benefits of  detemirs’ weight advantage in term 
of cardiovascular risk would be difficult to assess. On the 
other hand, insulin detemir has a shorter half live compared 
with glargine and NPH with up to half of patients ending up Vascular Health and Risk Management 2009:5 559
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on twice daily dose compared with once daily dose for the 
other two basal insulins.
Insulin detemir is therefore a rational choice for use as 
once daily or twice daily basal insulin in type 2 diabetes 
either in a basal-bolus regimen or ass add-on to OADs. 
The currently underway PREDICTIVE study is widely 
expected to contribute to the growing body of evidence on 
the efficacy and safety of insulin detemir in both type 1 and 
type 2 diabetes. It worth mentioning that the PREDICTIVE 
study is an open label trial with no control group and these 
factors should be taken in consideration before making any 
final conclusions from this project.
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